Humacyte Expands Global Commercial Strategy Through Realignment of Ex-U.S. Rights to Symvess

Key Developments Announced That May Impact Shareholder Value

Durham, N.C., April 24, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company specializing in bioengineered human tissues, announced a significant restructuring of its international commercial rights to Symvess, an acellular tissue engineered vessel (ATEV). The amendment to the company’s distribution agreement with its long-standing partner and largest shareholder, Fresenius Medical Care (FME), could have important implications for Humacyte’s international expansion and future growth prospects.

Key Points from the Announcement

• Ex-U.S. Commercial Rights Realigned: Humacyte now holds exclusive rights to distribute Symvess outside the United States. In return, Fresenius Medical Care will receive low-single-digit royalties on net sales of Symvess outside the U.S. The terms for U.S. distribution remain unchanged.
• Strategic Flexibility for International Partnerships: This realignment positions Humacyte to pursue discussions with potential corporate partners regarding both international and indication-specific rights to Symvess. The company is now better able to advance previously announced commercial initiatives in the Kingdom of Saudi Arabia and Israel, particularly in the field of vascular injury repair and other indications.
• Potential for Share Price Impact: By gaining exclusive ex-U.S. rights, Humacyte increases its potential for international revenue streams and strategic collaborations. This kind of realignment may be viewed positively by investors as it demonstrates Humacyte’s commitment to international growth and strategic flexibility.
• Product Approval and Pipeline Update:
  • Symvess has received FDA approval for the extremity vascular trauma indication (December 2024).
  • ATEVs are in late-stage clinical trials for other vascular applications, such as arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD).
  • Preclinical programs are advancing in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and other novel cell and tissue applications.
  • Humacyte’s 6mm ATEV for AV access was the first product candidate to receive both FDA’s Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
  • The 6mm ATEV for urgent arterial repair and advanced PAD have also received RMAT designations, as well as a priority designation for vascular trauma by the U.S. Secretary of Defense.
• Royalty Structure: The new agreement entitles Fresenius Medical Care to low-single-digit royalties on Humacyte’s ex-U.S. net sales of Symvess, aligning incentives for both companies and limiting Humacyte’s ongoing distribution costs.
• Regulatory Status Reminder: For uses beyond FDA-approved extremity vascular trauma, Symvess remains investigational and is not yet approved for sale by the FDA or any other regulatory body.

Important Considerations for Shareholders

• Strategic Control: Humacyte’s exclusive ex-U.S. rights could unlock significant new markets and collaboration opportunities, potentially driving future revenue growth.
• Potential Share Price Sensitivity: The realignment strengthens Humacyte’s negotiating position for future deals and may be perceived as a value-accretive corporate action. Investors should watch for further updates on international partnerships and market launches.
• Execution Risks: As with any pipeline and commercial expansion, there are risks related to regulatory approvals, market acceptance, manufacturing scale-up, and reimbursement. The company has highlighted these forward-looking uncertainties.
• Focus on Cost Management: Humacyte continues to pursue cost-saving measures and asset optimization, with potential for further actions or asset impairment charges if required to preserve shareholder value.

Forward-Looking Statements and Risks

Investors should note that this announcement includes forward-looking statements regarding Humacyte’s ability to commercialize Symvess (including in Saudi Arabia and Israel), market acceptance, manufacturing, development timelines, and regulatory approvals. Actual outcomes could differ due to risks such as changes in laws, economic or business conditions, strategic execution, and regulatory hurdles. The company refers investors to its SEC filings, including the Annual Report on Form 10-K for the year ended December 31, 2025, for a full discussion of risk factors.

Investor and Media Contacts

• Investor Relations: Joyce Allaire, LifeSci Advisors LLC, +1-617-435-6602, [email protected], [email protected]
• Media Relations: Rich Luchette, Precision Strategies, +1-202-845-3924, [email protected], [email protected]

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consult their financial advisors before making investment decisions. This summary is based on company press releases and public filings and may include forward-looking statements subject to risks and uncertainties.

View Humacyte, Inc. Historical chart here